Synapse - Hani Hassoun

Results (339)

Cisplatin-based chemotherapy is associated with an unacceptably high incidence of thromboembolic events: A large retrospective analysis

Meeting Abstract

Moore, R. A.; Adel, N. G.; Bhutani, M.; Tabbara, N. E.; Landau, H.; Nimer, S. D.; Feldman, D. R.; Hassoun, H.
Blood (2009)

Fulltext@MSK | Save

Adjuvant bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic light-chain amyloidosis (AL): A phase II study

Meeting Abstract

Landau, H.; Hassoun, H.; Cohen, A. D.; Lesokhin, A.; Bello, C.; Hoover, E.; Riedel, E. R.; Ciminiello, J.; McCullagh, E.; Nimer, S. D.; more...
Blood (2009)

Fulltext@MSK | Save

Single-agent bortezomib in previously untreated multiple myeloma: Efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy

Journal Article

Richardson, P. G.; Xie, W. L.; Mitsiades, C.; Chanan-Khan, A. A.; Lonial, S.; Hassoun, H.; Avigan, D. E.; Oaklander, A. L.; Kuter, D. J.; Wen, P. Y.; more...
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

Cutaneous and central nervous system involvement in multiple myeloma

Meeting Abstract

Karam, S.; Matushansky, I.; Hassoun, H.
Journal of General Internal Medicine (2009)

Fulltext@MSK | Save

CD32B expression reflects intraclonal functional heterogeity in multiple myeloma

Meeting Abstract

Comenzo, R. L.; Jhanwar, S. C.; Nimer, S. D.; Zhou, P.; Boruchov, A.; Lu, P.; Bonvini, E.; Hassoun, H.
Clinical Lymphoma and Myeloma (2009)

Fulltext@MSK | Save

Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma

Journal Article

Motzer, R. J.; Feldman, D. R.; Baum, M. S.; Ginsberg, M. S.; Hassoun, H.; Flombaum, C. D.; Velasco, S.; Fischer, P.; Ronnen, E.; Ishill, N.; more...
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

Phase I trial of bevacizumab plus sunitinib in patients with metastatic renal cell carcinoma

Meeting Abstract

Feldman, D. R.; Ginsberg, M. S.; Baum, M.; Flombaum, C.; Hassoun, H.; Velasco, S.; Fischer, P.; Ishill, N. M.; Ronnen, E. A.; Motzer, R. J.
Journal of Clinical Oncology (2008)

Fulltext@MSK | Save

Risk-adapted melphalan with stem cell transplant (SCT) and adjuvant dexamethasone (dex) +/- thalidomide (thal) achieves low treatment related mortality and high hematologic response rates

Book Section

Cohen, A. D.; Zhou, P.; Reich, L.; Hassoun, H.; Teruya-Feldstein, J.; Filippa, D. A.; Clark, B.; Stubblefield, M.; Fleisher, M.; Nimer, S. D.; more...
In Skinner, M.; Berk, J. L.; Connors, L. H.; Seldin, D. C. (Eds.) XIth International Symposium on Amyloidosis (2008)

Fulltext@MSK | Save

CD32B expression reflects phenotypic and functional heterogeneity in multiple myeloma (MM)

Meeting Abstract

Zhou, P.; Boruchov, A. M.; Hoffman, J. E.; Mo, Q. X.; Olshen, A.; Glasner, E.; Bonvini, E.; Koenig, S.; Drieghe, E.; Fleisher, M.; more...
Blood (2008)

Fulltext@MSK | Save

Sequential administration of bortezomib, liposomal doxorubicin and dexamethasone (BDD) followed by thalidomide and dexamethasone (TD) results in rapid control of untreated high-risk multiple myeloma (MM) and improves depth of response

Meeting Abstract

Landau, H.; Hassoun, H.; Cohen, A.; Hoover, E.; Kewalramani, T.; Boruchov, A.; Klimek, V.; Reich, L.; Riedel, E.; Pandit-Taskar, N.; more...
Blood (2008)

Fulltext@MSK | Save